Burning Rock Biotech Ltd
Company Profile
Business description
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
Contact
No. 5, Xingdao Ring Road North
International Bio Island
Guangzhou510005
CHNT: +86 2034037871
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
667
Stocks News & Analysis
stocks
After earnings, is Microsoft a buy, a sell, or fairly valued?
stocks
Albemarle earnings: Shares rally on strong profit growth well above consensus estimates
stocks
Ahead of IPOs, AI giants keep making circular deals. Here’s why that’s a risk - Clone
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,964.70 | 47.40 | -0.53% |
| CAC 40 | 8,202.08 | 97.34 | -1.17% |
| DAX 40 | 24,663.61 | 255.08 | -1.02% |
| Dow JONES (US) | 49,596.97 | 313.62 | -0.63% |
| FTSE 100 | 10,276.95 | 161.71 | -1.55% |
| HKSE | 26,335.94 | 290.34 | -1.09% |
| NASDAQ | 25,806.20 | 32.75 | -0.13% |
| Nikkei 225 | 62,431.90 | 401.94 | -0.64% |
| NZX 50 Index | 13,189.87 | 80.74 | -0.61% |
| S&P 500 | 7,337.11 | 28.01 | -0.38% |
| S&P/ASX 200 | 8,730.30 | 50.50 | -0.58% |
| SSE Composite Index | 4,162.27 | 17.82 | -0.43% |